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Abstract
Cardiac arrhythmias and syncope are rare consequence of therapy with pegylated interferon. We
report a 55-year-old Egyptian woman who developed palpitation and syncopal attacks twice within
3 months after starting therapy with pegylated interferon a2b and ribavirin for the treatment
of chronic hepatitis C virus. Hepatitis C virus-RNA was undetectable after 12 week. The
electrocardiogram holter revealed ventricular extra-systoles on top of sinus tachycardia. pegylated
interferon a2b therapy was continued but with a reduced dose. Close follow up revealed neither
palpitation nor syncope and hepatitis C virus-RNA was undetectable at 24 and 48 weeks of
treatment. In conclusion, our study suggests readjustment of the dose of pegylated interferon a2b
therapy to avoid these serious side effects.
Introduction
Chronic hepatitis C affects 300 million people worldwide
[1]. Treatment of hepatitis C virus (HCV) with interferon
alpha 2b (IFN) and ribavirin therapy has been shown to be
effective, with 41-47% of patients achieving a sustained
virologic response [2]. A regimen of peginterferon a2b
(peg-IFN) and ribavirin has proven to be more effective
than a regimen of conventional interferon and ribavirin
with overall sustained virologic response rates 54-56%
[3-5].
In spite of the current popularity of peg-IFN a2b and
ribavirin therapy, many side effects have been reported
[6]. Flu-like symptoms such as fever, chills, muscle ache;
nausea, vomiting, and fatigue are common side effects of
treatment. Depression and related symptoms, such as
anxiety, irritability, insomnia, and mental confusion, are
not rare and may be significant in patients with a previous
history. Common hematologic side effects that require
monitoring include neutropenia and thrombocytopenia.
Withdrawal rates in IFN-based combination studies due to
side effects have ranged from 6% to 7% [7].
In addition, Peg-IFN therapy has been reported to affect
cardio-vascular system (cardiac arrhythmia) as reported
in product information. One study reported that un-
explained lipothymia (syncope or sudden fainting)
resulted in discontinuation of the treatment [8].
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Case presentation
A 55-years-old Egyptian woman with chronic hepatitis C
whose weight was 99 kg was treated with Peg-IFN-a2b at a
dose of 1.5 mg/kg per week subcutaneously (150 mg/week)
and ribavirin 1200 mg/day. Her drug and past medical
history was unremarkable, she was not hypertensive nor
had cardiac abnormalities. Her basic resting ECG was
normal. Her hemoglobin (Hb) was 14.9 g/dl. Her follow
up on week 1, 2 and 4 showed no problems except a
reasonable progressive decrease of her Hb to 12.5. On
week 8, she complained of dyspnea grade II and dizzy
spills; her Hb was 11.1 g/dl. The ribavirin was decreased to
1000 mg/day. On week 12, her HCV-RNA level estimated
by sensitive polymerase chain reaction (PCR)-based assay
was negative, but unfortunately, she complained of two
attacks of palpation followed by syncopal attacks. An ECG
holter to monitor her cardiac arrhythmia and echocardio-
graphy and testing her electrolytes were done. ECG holter
revealed ventricular ectopic activity in the form of unifocal
ventricular extrasystoles (VES) and sinus tachycardia (Max
HR was 156 beats/min).
Echocardiography was normal. Electrolytes and thyroid
profile were within normal range. Finally, the medication
was continued but it was decreased to 120 mg/week.
Follow up did not show any more palpitation, syncopal
attacks or other side effects. Treatment was continued for
48 weeks continuously. The HCV RNA on week 24 and
48 was undetectable.
Discussion
Side effects of IFN and ribavirin combination therapy for
HCV have been documented; however, cardiac arrhythmia
and syncopal attacks are rare reported side effects [9].
Cardiac arrhythmia is reported only in the Peg interferon
product information and one big study conducted on 441
chronic HCV patients reported that unexplained syncopal
attacks occurred in 11 patients resulting in discontinuation
of the treatment [8].
Therefore, any syncopal attacks should be fully investi-
gated before discontinuing the medication and the risk -
benefit should be explored.
Conclusion
In conclusion, dose readjustment instead of discontinua-
tion of IFN can be beneficial in dealing with these serious
side effects without changing the viral response rate.
However, further research is needed to delineate optimal
therapeutic strategies in larger studies.
Patient’s perspective
I was infected with chronic hepatitis C. Then after starting
my treatment, I suffered from irregular heartbeats followed





Written informed consent was obtained from the patient
for publication of this case report. A copy of the written
consent is available for review by the Editor-in-Chief of
this journal.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KEA: diagnosed and followed up the patient and involved
in writing the manuscript. HTE: made contribution to
conception and design of the study and involved in
drafting the manuscript and revised it. Authors read and
approved the final manuscript.
References
1. Patrick DM, Buxton JA, Bigham M, Mathias RG: Public health and
hepatitis C. Can J Public Health 2000, 91:S18-S23.
2. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C,
Dienstag J, Lee WM, Jak C, Garaud JJ, Albrecht JK: International
Hepatitis Interventional Therapy Group. Adherence to
combination therapy enhances sustained response in geno-
type-1-infected patients with chronic hepatitis C. Gastroenter-
ology 2002, 123:1061-1069.
3. Fried MW, Schiffman ML, Reddy KR, Smith C, Marinos G,
Goncales FL Jr, Haussinger D, Diago M, Carosi G, Dhumeaux D,
Craxi A, Lin A, Hoffman J, Yu J: Peginterferon alfa-2a plus
ribavirin for chronic hepatitis C virus infection. N Engl J Med
2002, 347:975-982.
4. Hadziyannis SJ, Sette H Jr, Morgan TR, Balan V, Diago M, Marcellin P,
Ramadori G, Bodenheimer H Jr, Bernstein D, Rizzetto M, Zeuzem S,
Pockros PJ, Lin A, Ackrill AM: PEGASYS International Study
Group. Ann Intern Med 2004, 140:346-355.
5. Kang MJ, Jung EU, Park SW, Choi P, Kim JH, Park SJ, Park ET, Lee YJ,
Lee SH, Seol SY: Effects of pegylated interferon and ribavirin in
Korean patients with chronic hepatitis C virus infection.
Korean J Hepatol 2008, 14:318-330.
6. Martin P, Jensen D: Ribavirin in the Treatment of Chronic
Hepatitis C. J Gastroenterol Hepatol 2008, 23:844-855.
7. Reichard O, Norkrans G, Fryden A, Braconier JH, Sonnerborg A,
Weiland O: Randomized, double-blind, placebo-controlled
trial of interferon alpha-2-b with and without ribavirin for
chronic hepatitis C. Lancet 1998, 351:83-87.
8. HCVAdvocate [http://www.hcvadvocate.org/news/review_archive_2002.
asp].
9. Okanoue T, Sakamoto S, Itoh Y, Minami M, Yasui K, Sakamoto M,
Nishioji K, Katagishi T, Nakagawa Y, Tada H, Sawa Y, Mizuno M,
Kagawa K, Kashima K: Side effects of high-dose interferon
therapy for chronic hepatitis C. J Hepatol Gastroenterol Clin Biol
1997, 21:157-158.
Page 2 of 2
(page number not for citation purposes)
Cases Journal 2009, 2:7429 http://casesjournal.com/casesjournal/article/view/7429
